According to clinical research, nearly 90 per cent of patients using CeQur Simplicity reported better adherence to their insulin regimen compared to multiple daily injections.
Brad Paddock, President and CEO of CeQur, stated, 'We are grateful for the support of our investors as we accelerate our mission to transform diabetes care.'
The CeQur Simplicity device holds up to 200 units of insulin and replaces an average of twelve daily mealtime injections over four days.
CeQur's device has been clinically proven to improve glycemic control, enabling patients to accomplish their A1C and time-in-range goals.
Collection
[
|
...
]